{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:09:02Z","timestamp":1778659742838,"version":"3.51.4"},"reference-count":216,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":99,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Targeted therapies are changing the landscape of pediatric brain tumor management. They offer the opportunity of more effective and personalized treatment strategies, with reduced side effects and improved outcomes. This paradigm shift in pediatric neuro-oncology is still at an early stage, and this review summarizes ongoing research that aims at finding novel drugs or at improving the management of pediatric low- and high-grade gliomas, ependymomas, embryonal tumors, germ cell tumors, craniopharyngiomas, and choroid plexus carcinomas.<\/jats:p>","DOI":"10.1093\/noajnl\/vdaf188","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:44:33Z","timestamp":1756295073000},"page":"ii78-ii91","source":"Crossref","is-referenced-by-count":0,"title":["The future of targeted therapies for pediatric central nervous system tumors"],"prefix":"10.1093","volume":"8","author":[{"given":"Holly","family":"Lindsay","sequence":"first","affiliation":[{"name":"Center for Cancer and Blood Disorders, Children\u2019s Hospital Colorado Anschutz Medical Campus, University of Colorado School of Medicine , Denver, Colorado ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6832-6539","authenticated-orcid":false,"given":"Eric","family":"Bouffet","sequence":"additional","affiliation":[{"name":"Hospital for Sick Children, The University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"834","key":"2026051303211725300_CIT0001","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur J Pharmacol."},{"issue":"1","key":"2026051303211725300_CIT0002","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11033-023-09096-8","article-title":"Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy","volume":"51","author":"Zafar","year":"2024","journal-title":"Mol Biol Rep."},{"issue":"10229","key":"2026051303211725300_CIT0003","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2026051303211725300_CIT0004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1146\/annurev-genom-091416-035434","article-title":"Tailoring medulloblastoma treatment through genomics: making a change, one subgroup at a time","volume":"18","author":"Holgado","year":"2017","journal-title":"Annu Rev Genomics Hum Genet."},{"issue":"1","key":"2026051303211725300_CIT0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev-pharmtox-010715-103440","article-title":"Drugging undruggable molecular cancer targets","volume":"56","author":"Lazo","year":"2016","journal-title":"Annu Rev Pharmacol Toxicol."},{"issue":"4","key":"2026051303211725300_CIT0006","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00401-022-02405-8","article-title":"The oncogenic fusion landscape in pediatric CNS neoplasms","volume":"143","author":"Roosen","year":"2022","journal-title":"Acta Neuropathol."},{"issue":"4","key":"2026051303211725300_CIT0007","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.21873\/anticanres.14936","article-title":"New approaches in targeted therapy for medulloblastoma in children","volume":"41","author":"Maier","year":"2021","journal-title":"Anticancer Res."},{"issue":"12","key":"2026051303211725300_CIT0008","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1177\/0883073820931635","article-title":"Molecular-targeted therapy for childhood brain tumors: a moving target","volume":"35","author":"Packer","year":"2020","journal-title":"J Child Neurol."},{"issue":"7","key":"2026051303211725300_CIT0009","doi-asserted-by":"crossref","first-page":"e28338","DOI":"10.1002\/pbc.28338","article-title":"Tumor mutational burden and driver mutations: characterizing the genomic landscape of pediatric brain tumors","volume":"67","author":"Patel","year":"2020","journal-title":"Pediatr Blood Cancer."},{"issue":"1","key":"2026051303211725300_CIT0010","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40478-020-00953-2","article-title":"Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients","volume":"8","author":"Guntner","year":"2020","journal-title":"Acta Neuropathol Commun."},{"issue":"1","key":"2026051303211725300_CIT0011","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/jpet.112.192195","article-title":"Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)","volume":"342","author":"Mittapalli","year":"2012","journal-title":"J Pharmacol Exp Ther."},{"issue":"9829","key":"2026051303211725300_CIT0012","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet."},{"issue":"21","key":"2026051303211725300_CIT0013","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.18632\/oncotarget.27600","article-title":"Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)","volume":"11","author":"Nicolaides","year":"2020","journal-title":"Oncotarget."},{"issue":"12","key":"2026051303211725300_CIT0014","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N Engl J Med."},{"issue":"2","key":"2026051303211725300_CIT0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1215\/15228517-2006-031","article-title":"Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report","volume":"9","author":"Pollack","year":"2007","journal-title":"Neuro Oncol."},{"issue":"3","key":"2026051303211725300_CIT0016","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/neuonc\/noq202","article-title":"Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas","volume":"13","author":"Haas-Kogan","year":"2011","journal-title":"Neuro Oncol."},{"issue":"6","key":"2026051303211725300_CIT0017","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/neuonc\/noaa016","article-title":"A phase I\/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a pediatric brain tumor consortium study","volume":"22","author":"Baxter","year":"2020","journal-title":"Neuro Oncol"},{"issue":"12","key":"2026051303211725300_CIT0018","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/neuonc\/noad141","article-title":"Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium (PBTC-047)","volume":"25","author":"Monje","year":"2023","journal-title":"Neuro Oncol."},{"issue":"3","key":"2026051303211725300_CIT0019","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/neuonc\/noq199","article-title":"A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the pediatric brain tumor consortium","volume":"13","author":"Pollack","year":"2011","journal-title":"Neuro Oncol."},{"issue":"11","key":"2026051303211725300_CIT0020","doi-asserted-by":"crossref","first-page":"e1009868","DOI":"10.1371\/journal.pgen.1009868","article-title":"The H3.3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma","volume":"17","author":"Bo\u010dkaj","year":"2021","journal-title":"PLoS Genet."},{"issue":"7409","key":"2026051303211725300_CIT0021","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature11284","article-title":"Dissecting the genomic complexity underlying medulloblastoma","volume":"488","author":"Jones","year":"2012","journal-title":"Nature."},{"issue":"10","key":"2026051303211725300_CIT0022","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1007\/s00381-024-06486-6","article-title":"Molecular-targeted therapy for childhood low-grade glial and glioneuronal tumors","volume":"40","author":"Siegel","year":"2024","journal-title":"Childs Nerv Syst."},{"issue":"8","key":"2026051303211725300_CIT0023","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/neuonc\/noae074","article-title":"Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: a modified Delphi approach to build international consensus-based definitions\u2014International Pediatric Low-Grade Glioma Coalition","volume":"26","author":"O\u2019Hare","year":"2024","journal-title":"Neuro Oncol."},{"issue":"Suppl 4","key":"2026051303211725300_CIT0024","first-page":"0","article-title":"LGG-50. Poor response to MEKi re-initiation in pediatric low-grade glioma after treatment discontinuation. A pLGG Taskforce study","volume":"26","author":"Bajin","year":"2024","journal-title":"Neuro Oncol."},{"issue":"4","key":"2026051303211725300_CIT0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/PO.19.00298","article-title":"Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition","volume":"561","author":"Nobre","year":"2020","journal-title":"JCO Precis Oncol."},{"issue":"7","key":"2026051303211725300_CIT0026","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.3390\/curroncol31070299","article-title":"Canadian consensus for treatment of BRAF V600E mutated pediatric and AYA gliomas","volume":"31","author":"Erker","year":"2024","journal-title":"Curr Oncol."},{"key":"2026051303211725300_CIT0027","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.03.025","article-title":"Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non\u2013small cell lung cancer","volume":"132","author":"Facchinetti","year":"2020","journal-title":"Eur J Cancer."},{"issue":"1176","key":"2026051303211725300_CIT0028","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/cancers11081176","article-title":"Adaptive responses as mechanisms of resistance to BRAF inhibitors in melanoma","volume":"11","author":"Saei","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"424","key":"2026051303211725300_CIT0029","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/life11050424","article-title":"Many distinct ways lead to drug resistance in BRAF- and NRAS-mutated melanomas","volume":"11","author":"Vachtenheim","year":"2021","journal-title":"Life."},{"issue":"7","key":"2026051303211725300_CIT0030","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"2026051303211725300_CIT0031","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat Med."},{"issue":"10","key":"2026051303211725300_CIT0032","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1007\/s00381-024-06504-7","article-title":"Future perspective of targeted treatments in pediatric low-grade glioma (pLGG): the evolution of standard-of-care and challenges of a new era","volume":"40","author":"Plant-Fox","year":"2024","journal-title":"Childs Nerv Syst."},{"key":"2026051303211725300_CIT0033","doi-asserted-by":"crossref","first-page":"1074726","DOI":"10.3389\/fonc.2022.1074726","article-title":"Response and resistance to BRAFV600E inhibition in gliomas: roadblocks ahead","volume":"12","author":"Capogiri","year":"2023","journal-title":"Front Oncol."},{"issue":"4","key":"2026051303211725300_CIT0034","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","article-title":"Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations","volume":"5","author":"Ahronian","year":"2015","journal-title":"Cancer Discov."},{"issue":"9","key":"2026051303211725300_CIT0035","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1158\/2159-8290.CD-24-0024","article-title":"A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov."},{"issue":"11","key":"2026051303211725300_CIT0036","doi-asserted-by":"crossref","first-page":"1052\u20131059","DOI":"10.1093\/jnen\/nlab097","article-title":"Molecular alterations in pediatric low-grade gliomas that led to death","volume":"80","author":"Ahrendsen","year":"2021","journal-title":"J Neuropathol Exp Neurol."},{"issue":"5","key":"2026051303211725300_CIT0037","first-page":"e4726","article-title":"Clinical importance of CDKN2A loss and monosomy 10 in pilocytic astrocytoma","volume":"11","author":"Cagney","year":"2019","journal-title":"Cureus."},{"issue":"22","key":"2026051303211725300_CIT0038","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1158\/1078-0432.CCR-21-2660","article-title":"Deconvoluting mechanisms of acquired resistance to RAF inhibitors in BRAFV600E-mutant human glioma","volume":"27","author":"Schreck","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"7","key":"2026051303211725300_CIT0039","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1158\/2159-8290.CD-14-0049","article-title":"Autophagy inhibition improves chemosensitivity in BRAFV600E brain tumors","volume":"4","author":"Levy","year":"2014","journal-title":"Cancer Discov."},{"issue":"suppl 1","key":"2026051303211725300_CIT0040","doi-asserted-by":"crossref","first-page":"i35","DOI":"10.1093\/neuonc\/noac079.129","article-title":"EPCT-01. Pediatric brain tumor consortium (PBTC)-055: a phase I study of trametinib and hydroxychloroquine (HCQ) for BRAF-fusion or neurofibromatosis type-1 (NF1)-associated pediatric gliomas","volume":"24","author":"Hoffman","year":"2022","journal-title":"Neuro-Oncology."},{"issue":"48","key":"2026051303211725300_CIT0041","doi-asserted-by":"crossref","first-page":"34045","DOI":"10.1039\/D3RA06434D","article-title":"Evolving approaches in glioma treatment: harnessing the potential of copper metabolism modulation","volume":"13","author":"Cazzoli","year":"2023","journal-title":"RSC Adv."},{"issue":"7","key":"2026051303211725300_CIT0042","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/1541-7786.MCR-21-0250","article-title":"BRAFV600E-driven lung adenocarcinoma requires copper to sustain autophagic signaling and processing","volume":"20","author":"Tsang","year":"2022","journal-title":"Mol Cancer Res."},{"issue":"22","key":"2026051303211725300_CIT0043","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1158\/0008-5472.CAN-16-1190","article-title":"Copper chelation inhibits BRAFV600E-driven melanomagenesis and counters resistance to BRAFV600E and MEK1\/2 inhibitors","volume":"77","author":"Brady","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"2026051303211725300_CIT0044","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1038\/s41467-023-40235-8","article-title":"MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas","volume":"14","author":"Sigaud","year":"2023","journal-title":"Nat Commun."},{"issue":"1","key":"2026051303211725300_CIT0045","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1038\/s41467-024-49595-1","article-title":"Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment","volume":"15","author":"Levine","year":"2024","journal-title":"Nat Commun."},{"issue":"6","key":"2026051303211725300_CIT0046","doi-asserted-by":"crossref","first-page":"102183","DOI":"10.1016\/j.xcrm.2025.102183","article-title":"BRAF\/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAFV600E-mutant glioma","volume":"6","author":"Xing","year":"2025","journal-title":"Cell Rep Med."},{"issue":"33","key":"2026051303211725300_CIT0047","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1200\/JCO.23.00558","article-title":"Phase II trial of dabrafenib plus trametinib in relapsed\/refractory BRAF V600\u2013mutant pediatric high-grade glioma","volume":"41","author":"Hargrave","year":"2023","journal-title":"J Clin Oncol."},{"issue":"11","key":"2026051303211725300_CIT0048","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/neuonc\/noad125","article-title":"Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation","volume":"25","author":"Milde","year":"2023","journal-title":"Neuro Oncol."},{"issue":"3","key":"2026051303211725300_CIT0049","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/neuonc\/noac183","article-title":"The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models","volume":"25","author":"Sigaud","year":"2023","journal-title":"Neuro Oncol."},{"key":"2026051303211725300_CIT0050","doi-asserted-by":"crossref","first-page":"e2400103","DOI":"10.1200\/PO.24.00103","article-title":"Phase II study of ulixertinib in children and young adults with tumors harboring activating mitogen-activated protein kinase pathway alterations: APEC1621J of the National Cancer Institute-Children\u2019s Oncology Group Pediatric MATCH Trial","volume":"8","author":"Vo","year":"2024","journal-title":"JCO Precis Oncol."},{"issue":"4","key":"2026051303211725300_CIT0051","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/neuonc\/noac199","article-title":"BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma","volume":"25","author":"Selt","year":"2023","journal-title":"Neuro Oncol."},{"issue":"5","key":"2026051303211725300_CIT0052","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/PO.20.00444","article-title":"Debio1347, an oral FGFR inhibitor: results from a single-center study in pediatric patients with recurrent or refractory FGFR-altered gliomas","volume":"876","author":"Farouk Sait","year":"2021","journal-title":"JCO Precis Oncol."},{"issue":"3","key":"2026051303211725300_CIT0053","doi-asserted-by":"crossref","first-page":"e30836","DOI":"10.1002\/pbc.30836","article-title":"Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients","volume":"71","author":"Stepien","year":"2024","journal-title":"Pediatr Blood Cancer."},{"issue":"9","key":"2026051303211725300_CIT0054","doi-asserted-by":"crossref","first-page":"e29921","DOI":"10.1002\/pbc.29921","article-title":"Slipped capital femoral epiphyses: a major on-target adverse event associated with FGFR tyrosine kinase inhibitors in pediatric patients","volume":"70","author":"Farouk Sait","year":"2023","journal-title":"Pediatr Blood Cancer."},{"issue":"11","key":"2026051303211725300_CIT0055","doi-asserted-by":"crossref","first-page":"e30887","DOI":"10.1016\/j.heliyon.2024.e30887","article-title":"Skeletal overgrowth in a pre-pubescent child treated with pan-FGFR inhibitor","volume":"10","author":"Majlessipour","year":"2024","journal-title":"Heliyon."},{"issue":"7","key":"2026051303211725300_CIT0056","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med."},{"key":"2026051303211725300_CIT0057","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-025-00962-x","article-title":"A population-based analysis of the molecular landscape of glioma in adolescents and young adults reveals insights into gliomagenesis","author":"Bennett","year":"2025","journal-title":"Nat Cancer."},{"issue":"1","key":"2026051303211725300_CIT0058","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1038\/s41467-019-12187-5","article-title":"Alterations in ALK\/ROS1\/NTRK\/MET drive a group of infantile hemispheric gliomas","volume":"10","author":"Guerreiro Stucklin","year":"2019","journal-title":"Nat Commun."},{"issue":"6","key":"2026051303211725300_CIT0059","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/neuonc\/noab274","article-title":"Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors","volume":"24","author":"Doz","year":"2022","journal-title":"Neuro Oncol."},{"key":"2026051303211725300_CIT0060","doi-asserted-by":"crossref","first-page":"e2200255","DOI":"10.1200\/PO.22.00255","article-title":"Lorlatinib for the treatment of ALK fusion\u2013positive infant-type hemispheric glioma: a case report","volume":"6","author":"Greenwell","year":"2022;","journal-title":"JCO Precis Oncol."},{"issue":"7","key":"2026051303211725300_CIT0061","doi-asserted-by":"crossref","first-page":"e30312","DOI":"10.1002\/pbc.30312","article-title":"Significant response to targeted treatment with alectinib for intramedullary pediatric spinal high-grade glioma with ALK fusion","volume":"70","author":"Ringel","year":"2023","journal-title":"Pediatr Blood Cancer."},{"issue":"10","key":"2026051303211725300_CIT0062","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/neuonc\/noac087","article-title":"Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)","volume":"24","author":"Desai","year":"2022","journal-title":"Neuro Oncol."},{"issue":"19","key":"2026051303211725300_CIT0063","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.3390\/cancers16193395","article-title":"Tissue-agnostic targeting of neurotrophic tyrosine receptor kinase fusions: current approvals and future directions","volume":"16","author":"Gouda","year":"2024","journal-title":"Cancers (Basel)."},{"issue":"1","key":"2026051303211725300_CIT0064","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0092-8674(05)80088-1","article-title":"Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death","volume":"75","author":"Klein","year":"1993","journal-title":"Cell."},{"issue":"2","key":"2026051303211725300_CIT0065","first-page":"245","article-title":"Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience","volume":"28","author":"Duffner","year":"1996","journal-title":"J Neurooncol."},{"issue":"7","key":"2026051303211725300_CIT0066","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/neuonc\/nos125","article-title":"Clinical and molecular characteristics of congenital glioblastoma","volume":"14","author":"Macy","year":"2012","journal-title":"Neuro Oncol."},{"issue":"suppl 4","key":"2026051303211725300_CIT0067","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1093\/neuonc\/noae064.162","article-title":"TRLS-09. CONNECT1903: a pilot and surgical study of larotrectinib for treatment of children with newly diagnosed HGG with NTRK fusion (NCT04655404)","volume":"26","author":"Chi","year":"2024","journal-title":"Neuro Oncol."},{"issue":"11","key":"2026051303211725300_CIT0068","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/neuonc\/noac096","article-title":"Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma","volume":"24","author":"Rosenberg","year":"2022","journal-title":"Neuro Oncol."},{"issue":"6","key":"2026051303211725300_CIT0069","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00401-020-02155-5","article-title":"Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition","volume":"139","author":"Mondal","year":"2020","journal-title":"Acta Neuropathol."},{"key":"2026051303211725300_CIT0070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.wneu.2021.03.009","article-title":"Precision medicine in pediatric bithalamic glioma: significance of the EGFR exon 20 insertion mutation","volume":"149","author":"Goyal","year":"2021","journal-title":"World Neurosurg."},{"issue":"8","key":"2026051303211725300_CIT0071","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR\u2013MET bispecific antibody, in diverse models of EGFR exon 20 insertion\u2013driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov."},{"issue":"7","key":"2026051303211725300_CIT0072","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.3390\/ijms25073992","article-title":"Mobocertinib in patients with EGFR exon 20 insertion-positive non-small cell lung cancer (MOON): an international real-world safety and efficacy analysis","volume":"25","author":"Illini","year":"2024","journal-title":"Int J Mol Sci ."},{"key":"2026051303211725300_CIT0073","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fonc.2014.00067","article-title":"Phase II trial of erlotinib during and after radiotherapy in children with newly diagnosed high-grade gliomas","volume":"4","author":"Qaddoumi","year":"2014","journal-title":"Front Oncol."},{"issue":"1","key":"2026051303211725300_CIT0074","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/neuonc\/noq141","article-title":"Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing\/refractory brain tumors","volume":"13","author":"Geoerger","year":"2011","journal-title":"Neuro Oncol."},{"key":"2026051303211725300_CIT0075","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2023.04.007","article-title":"Afatinib in paediatric patients with recurrent\/refractory ErbB-dysregulated tumours: results of a phase I\/expansion trial","volume":"188","author":"Geoerger","year":"2023","journal-title":"Eur J Cancer."},{"issue":"suppl 2","key":"2026051303211725300_CIT0076","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1093\/neuonc\/noad220","article-title":"H3 K27M-altered glioma and diffuse intrinsic pontine glioma: semi-systematic review of treatment landscape and future directions","volume":"26","author":"van den Bent","year":"2024","journal-title":"Neuro Oncol."},{"issue":"12","key":"2026051303211725300_CIT0077","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.neo.2020.09.005","article-title":"ONC201 and imipridones: anti-cancer compounds with clinical efficacy","volume":"22","author":"Prabhu","year":"2020","journal-title":"Neoplasia."},{"issue":"45","key":"2026051303211725300_CIT0078","doi-asserted-by":"crossref","first-page":"79298","DOI":"10.18632\/oncotarget.17837","article-title":"A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma","volume":"8","author":"Arrillaga-Romany","year":"2017","journal-title":"Oncotarget."},{"issue":"35","key":"2026051303211725300_CIT0079","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1200\/JCO.24.00709","article-title":"Comments and controversies in oncology: the tribulations of trials developing ONC201","volume":"42","author":"Hansford","year":"2024","journal-title":"J Clin Oncol."},{"issue":"8046","key":"2026051303211725300_CIT0080","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature."},{"key":"2026051303211725300_CIT0081","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2016.10.013","article-title":"Current therapy and the evolving molecular landscape of paediatric ependymoma","volume":"70","author":"Khatua","year":"2017","journal-title":"Eur J Cancer."},{"issue":"1","key":"2026051303211725300_CIT0082","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11060-015-1764-7","article-title":"An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)","volume":"123","author":"DeWire","year":"2015","journal-title":"J Neurooncol."},{"key":"2026051303211725300_CIT0083","doi-asserted-by":"crossref","first-page":"100895","DOI":"10.1016\/j.neo.2023.100895","article-title":"Why haven\u2019t we solved intracranial pediatric ependymoma? Current questions and barriers to treatment advances","volume":"39","author":"Hwang","year":"2023","journal-title":"Neoplasia."},{"issue":"4","key":"2026051303211725300_CIT0084","doi-asserted-by":"crossref","first-page":"e2319474122","DOI":"10.1073\/pnas.2319474122","article-title":"Targeting EPHB2\/ABL1 restores antitumor immunity in preclinical models of ependymoma","volume":"122","author":"Ren","year":"2025","journal-title":"Proc Natl Acad Sci USA."},{"issue":"614","key":"2026051303211725300_CIT0085","doi-asserted-by":"crossref","first-page":"eabc0497","DOI":"10.1126\/scitranslmed.abc0497","article-title":"Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas","volume":"13","author":"Panwalkar","year":"2021","journal-title":"Sci Transl Med."},{"issue":"5","key":"2026051303211725300_CIT0086","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/ng.3838","article-title":"Spatial heterogeneity in medulloblastoma","volume":"49","author":"Morrissy","year":"2017","journal-title":"Nat Genet."},{"issue":"6","key":"2026051303211725300_CIT0087","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1470-2045(18)30242-0","article-title":"Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort","volume":"19","author":"Waszak","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"2026051303211725300_CIT0088","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13311-017-0526-y","article-title":"Medulloblastoma: molecular classification-based personal therapeutics","volume":"14","author":"Archer","year":"2017","journal-title":"Neurotherapeutics."},{"issue":"3","key":"2026051303211725300_CIT0089","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/cas.15691","article-title":"Recent advances in the molecular understanding of medulloblastoma","volume":"114","author":"Funakoshi","year":"2023","journal-title":"Cancer Sci."},{"issue":"4","key":"2026051303211725300_CIT0090","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.devcel.2020.05.027","article-title":"DDX3X suppresses the susceptibility of hindbrain lineages to medulloblastoma","volume":"54","author":"Patmore","year":"2020","journal-title":"Dev Cell."},{"issue":"7","key":"2026051303211725300_CIT0091","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrd4233","article-title":"Can we safely target the WNT pathway","volume":"13","author":"Kahn","year":"2014","journal-title":"Nat Rev Drug Discov."},{"issue":"4","key":"2026051303211725300_CIT0092","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ccell.2016.03.002","article-title":"Medulloblastoma genotype dictates blood brain barrier phenotype","volume":"29","author":"Phoenix","year":"2016","journal-title":"Cancer Cell."},{"issue":"1","key":"2026051303211725300_CIT0093","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41568-019-0223-8","article-title":"Medulloblastomics revisited: biological and clinical insights from thousands of patients","volume":"20","author":"Hovestadt","year":"2020","journal-title":"Nat Rev Cancer."},{"key":"2026051303211725300_CIT0094","doi-asserted-by":"crossref","first-page":"566822","DOI":"10.3389\/fonc.2020.566822","article-title":"Cancer predisposition syndromes and medulloblastoma in the molecular era","volume":"10","author":"Carta","year":"2020","journal-title":"Front Oncol."},{"issue":"12","key":"2026051303211725300_CIT0095","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1158\/1078-0432.CCR-17-0595","article-title":"Cancer surveillance in Gorlin syndrome and rhabdoid tumor predisposition syndrome","volume":"23","author":"Foulkes","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2026051303211725300_CIT0096","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-019-0063-6","article-title":"Medulloblastoma","volume":"5","author":"Northcott","year":"2019","journal-title":"Nat Rev Dis Primers."},{"issue":"1","key":"2026051303211725300_CIT0097","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev-neuro-070815-013838","article-title":"Medulloblastoma: from molecular subgroups to molecular targeted therapies","volume":"41","author":"Wang","year":"2018","journal-title":"Annu Rev Neurosci."},{"issue":"24","key":"2026051303211725300_CIT0098","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1200\/JCO.2014.60.1591","article-title":"Vismodegib exerts targeted efficacy against recurrent sonic hedgehog\u2013subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032","volume":"33","author":"Robinson","year":"2015","journal-title":"J Clin Oncol."},{"issue":"7","key":"2026051303211725300_CIT0099","first-page":"79","article-title":"Targeting the medulloblastoma: a molecular-based approach","volume":"91","author":"Luzzi","year":"2020","journal-title":"Acta Biomed."},{"issue":"1","key":"2026051303211725300_CIT0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s40478-019-0773-8","article-title":"Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis","volume":"7","author":"Li","year":"2019","journal-title":"Acta Neuropathol Commun."},{"issue":"41","key":"2026051303211725300_CIT0101","doi-asserted-by":"crossref","first-page":"69295","DOI":"10.18632\/oncotarget.20619","article-title":"Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor","volume":"8","author":"Robinson","year":"2017","journal-title":"Oncotarget."},{"issue":"4","key":"2026051303211725300_CIT0102","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/neuonc\/noad191","article-title":"Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects","volume":"26","author":"Kresbach","year":"2024","journal-title":"Neuro Oncol."},{"issue":"24","key":"2026051303211725300_CIT0103","doi-asserted-by":"crossref","first-page":"16619","DOI":"10.18632\/oncotarget.24618","article-title":"Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy","volume":"9","author":"Chaturvedi","year":"2018","journal-title":"Oncotarget."},{"issue":"15","key":"2026051303211725300_CIT0104","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-11-0923","article-title":"Hedgehog fights back: mechanisms of acquired resistance against smoothened antagonists","volume":"71","author":"Metcalfe","year":"2011","journal-title":"Cancer Res."},{"issue":"3","key":"2026051303211725300_CIT0105","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ccell.2015.02.001","article-title":"Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma","volume":"27","author":"Sharpe","year":"2015","journal-title":"Cancer Cell."},{"issue":"8","key":"2026051303211725300_CIT0106","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.tips.2015.05.006","article-title":"Targeting GLI factors to inhibit the Hedgehog pathway","volume":"36","author":"Infante","year":"2015","journal-title":"Trends Pharmacol Sci."},{"issue":"7","key":"2026051303211725300_CIT0107","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/JCO.20.01372","article-title":"Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03)","volume":"39","author":"Gajjar","year":"2021","journal-title":"J Clin Oncol."},{"issue":"23","key":"2026051303211725300_CIT0108","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1200\/JCO.2012.48.5052","article-title":"Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma","volume":"31","author":"Zhukova","year":"2013","journal-title":"J Clin Oncol."},{"issue":"12","key":"2026051303211725300_CIT0109","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.ccell.2022.10.009","article-title":"Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma","volume":"40","author":"Gwynne","year":"2022","journal-title":"Cancer Cell."},{"issue":"4","key":"2026051303211725300_CIT0110","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1078-0432.CCR-13-2281","article-title":"BET bromodomain inhibition of MYC-amplified medulloblastoma","volume":"20","author":"Bandopadhayay","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2026051303211725300_CIT0111","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ccell.2014.11.002","article-title":"Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease","volume":"27","author":"Hill","year":"2015","journal-title":"Cancer Cell."},{"issue":"3","key":"2026051303211725300_CIT0112","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","article-title":"HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma","volume":"29","author":"Pei","year":"2016","journal-title":"Cancer Cell."},{"issue":"1","key":"2026051303211725300_CIT0113","doi-asserted-by":"crossref","first-page":"53","DOI":"10.21873\/anticanres.13925","article-title":"Targeting fibroblast growth factor receptor (FGFR) and phosphoinositide 3-kinase (PI3K) signaling pathways in medulloblastoma cell lines","volume":"40","author":"Holzhauser","year":"2020","journal-title":"Anticancer Res."},{"issue":"1","key":"2026051303211725300_CIT0114","doi-asserted-by":"crossref","first-page":"12822","DOI":"10.1038\/s41598-019-49299-3","article-title":"Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3K\u03b1 inhibition in medulloblastoma","volume":"9","author":"Eckerdt","year":"2019","journal-title":"Sci Rep."},{"issue":"2","key":"2026051303211725300_CIT0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/gcc.22018","article-title":"High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid\/rhabdoid tumors","volume":"52","author":"Hasselblatt","year":"2013","journal-title":"Genes Chromosomes Cancer."},{"issue":"8","key":"2026051303211725300_CIT0116","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1172\/JCI64400","article-title":"A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers","volume":"122","author":"Lee","year":"2012","journal-title":"J Clin Invest."},{"issue":"3","key":"2026051303211725300_CIT0117","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccell.2016.02.001","article-title":"Atypical teratoid\/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes","volume":"29","author":"Johann","year":"2016","journal-title":"Cancer Cell."},{"issue":"9","key":"2026051303211725300_CIT0118","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cancergen.2014.04.004","article-title":"Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth","volume":"207","author":"Kim","year":"2014","journal-title":"Cancer Genet."},{"issue":"6","key":"2026051303211725300_CIT0119","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ccell.2016.11.003","article-title":"Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors","volume":"30","author":"Torchia","year":"2016","journal-title":"Cancer Cell."},{"issue":"6","key":"2026051303211725300_CIT0120","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00401-022-02424-5","article-title":"ATRT\u2013SHH comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance","volume":"143","author":"Federico","year":"2022","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2026051303211725300_CIT0121","doi-asserted-by":"crossref","first-page":"e26218","DOI":"10.1002\/pbc.26218","article-title":"Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program","volume":"64","author":"Kurmasheva","year":"2017","journal-title":"Pediatr Blood Cancer."},{"issue":"1","key":"2026051303211725300_CIT0122","doi-asserted-by":"crossref","first-page":"9321","DOI":"10.1038\/s41467-024-53515-8","article-title":"Inhibiting EZH2 targets atypical teratoid rhabdoid tumor by triggering viral mimicry via both RNA and DNA sensing pathways","volume":"15","author":"Feng","year":"2024","journal-title":"Nat Commun."},{"issue":"2","key":"2026051303211725300_CIT0123","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/neuonc\/nos285","article-title":"Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells","volume":"15","author":"Alimova","year":"2013","journal-title":"Neuro Oncol."},{"issue":"5","key":"2026051303211725300_CIT0124","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1158\/1535-7163.MCT-21-0646","article-title":"Therapeutic targeting of EZH2 and BET BRD4 in pediatric rhabdoid tumors","volume":"21","author":"Ishi","year":"2022","journal-title":"Mol Cancer Ther."},{"issue":"19","key":"2026051303211725300_CIT0125","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"issue":"2","key":"2026051303211725300_CIT0126","doi-asserted-by":"crossref","first-page":"e28772","DOI":"10.1002\/pbc.28772","article-title":"In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models\u2014a report from the Pediatric Preclinical Testing Consortium","volume":"68","author":"Kurmasheva","year":"2021","journal-title":"Pediatr Blood Cancer."},{"key":"2026051303211725300_CIT0127","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2022.09.006","article-title":"Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors","volume":"27","author":"Shinohara","year":"2022","journal-title":"Mol Ther Oncolytics."},{"issue":"3645","key":"2026051303211725300_CIT0128","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.3390\/cancers14153645","article-title":"SMARCB1-deficient cancers: novel molecular insights and therapeutic vulnerabilities","volume":"14","author":"Cooper","year":"2022","journal-title":"Cancers (Basel)."},{"issue":"4","key":"2026051303211725300_CIT0129","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","article-title":"Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation","volume":"18","author":"Wilson","year":"2010","journal-title":"Cancer Cell."},{"issue":"1","key":"2026051303211725300_CIT0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11060-020-03639-w","article-title":"Atypical teratoid rhabdoid tumor: molecular insights and translation to novel therapeutics","volume":"150","author":"Nesvick","year":"2020","journal-title":"J Neurooncol."},{"issue":"11","key":"2026051303211725300_CIT0131","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/jnci\/djad085","article-title":"Tazemetostat for tumors harboring SMARCB1\/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C","volume":"115","author":"Chi","year":"2023","journal-title":"J Natl Cancer Inst."},{"issue":"16","key":"2026051303211725300_CIT0132","doi-asserted-by":"crossref","first-page":"10040","DOI":"10.1200\/JCO.2022.40.16_suppl.10040","article-title":"Update on phase 1 study of tazemetostat, an enhancer of zeste homolog 2 inhibitor, in pediatric patients with relapsed or refractory integrase interactor 1\u2013negative tumors","volume":"40","author":"Chi","year":"2022","journal-title":"J Clin Oncol."},{"issue":"2","key":"2026051303211725300_CIT0133","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/neuonc\/noac151","article-title":"Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid\/rhabdoid tumor","volume":"25","author":"Upadhyaya","year":"2023","journal-title":"Neuro Oncol."},{"issue":"10","key":"2026051303211725300_CIT0134","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-16-2898","article-title":"A Phase I Study of the CDK4\/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors","volume":"23","author":"Geoerger","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"suppl 2","key":"2026051303211725300_CIT0135","doi-asserted-by":"crossref","first-page":"ii63","DOI":"10.1093\/neuonc\/noz036.001","article-title":"ATRT-02. Therapeutic targeting of EZH2 and BET BRD4 in AT\/RT","volume":"21","author":"Zhang","year":"2019","journal-title":"Neuro Oncol."},{"issue":"1","key":"2026051303211725300_CIT0136","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s13046-023-02911-x","article-title":"Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor","volume":"42","author":"Giang","year":"2023","journal-title":"J Exp Clin Cancer Res."},{"issue":"3","key":"2026051303211725300_CIT0137","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/14728222.2022.2040017","article-title":"Atypical teratoid rhabdoid tumor (ATRT): disease mechanisms and potential drug targets","volume":"26","author":"Rechberger","year":"2022","journal-title":"Expert Opin Ther Targets."},{"issue":"3","key":"2026051303211725300_CIT0138","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3892\/ijo.2022.5322","article-title":"Targeting the TP53\/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors","volume":"60","author":"Alimova","year":"2022","journal-title":"Int J Oncol."},{"issue":"57","key":"2026051303211725300_CIT0139","doi-asserted-by":"crossref","first-page":"97290","DOI":"10.18632\/oncotarget.21932","article-title":"Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor","volume":"8","author":"Alimova","year":"2017","journal-title":"Oncotarget."},{"issue":"8","key":"2026051303211725300_CIT0140","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1158\/1541-7786.MCR-16-0432","article-title":"Therapeutic targeting of PTK7 is cytotoxic in atypical teratoid rhabdoid tumors","volume":"15","author":"Messerli","year":"2017","journal-title":"Mol Cancer Res."},{"issue":"2","key":"2026051303211725300_CIT0141","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00401-021-02328-w","article-title":"Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1\/INI1 protein in a molecular subset of atypical teratoid\/rhabdoid tumors","volume":"142","author":"Pathak","year":"2021","journal-title":"Acta Neuropathol."},{"issue":"7","key":"2026051303211725300_CIT0142","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3390\/ijms18071537","article-title":"BRD9 inhibition, alone or in combination with cytostatic compounds as a therapeutic approach in rhabdoid tumors","volume":"18","author":"Kr\u00e4mer","year":"2017","journal-title":"Int J Mol Sci ."},{"issue":"1","key":"2026051303211725300_CIT0143","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s41467-019-09891-7","article-title":"BRD9 defines a SWI\/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun."},{"issue":"9","key":"2026051303211725300_CIT0144","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1158\/0008-5472.CAN-18-3066","article-title":"MDM2 and MDM4 are therapeutic vulnerabilities in malignant rhabdoid tumors","volume":"79","author":"Howard","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"2026051303211725300_CIT0145","first-page":"vdad010","article-title":"The PARP inhibitor rucaparib synergizes with radiation to attenuate atypical teratoid rhabdoid tumor growth","volume":"5","author":"Alimova","year":"2023","journal-title":"Neurooncol. Adv.."},{"issue":"20","key":"2026051303211725300_CIT0146","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/s41388-023-02681-y","article-title":"Atypical teratoid\/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities","volume":"42","author":"Paassen","year":"2023","journal-title":"Oncogene."},{"issue":"11","key":"2026051303211725300_CIT0147","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.19.01776","article-title":"Efficacy of high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid\/rhabdoid tumor: a report from the Children\u2019s Oncology Group Trial ACNS0333","volume":"38","author":"Reddy","year":"2020","journal-title":"J Clin Oncol."},{"issue":"3","key":"2026051303211725300_CIT0148","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.2008.18.7724","article-title":"Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor","volume":"27","author":"Chi","year":"2009","journal-title":"J Clin Oncol."},{"issue":"3","key":"2026051303211725300_CIT0149","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00401-020-02182-2","article-title":"ETMR: a tumor entity in its infancy","volume":"140","author":"Lambo","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"7786","key":"2026051303211725300_CIT0150","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41586-019-1815-x","article-title":"The molecular landscape of ETMR at diagnosis and relapse","volume":"576","author":"Lambo","year":"2019","journal-title":"Nature."},{"issue":"12","key":"2026051303211725300_CIT0151","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/neuonc\/nox093","article-title":"Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients","volume":"19","author":"Schmidt","year":"2017","journal-title":"Neuro Oncol."},{"issue":"1","key":"2026051303211725300_CIT0152","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/neuonc\/not162","article-title":"A novel C19MC amplified cell line links Lin28\/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes","volume":"16","author":"Spence","year":"2014","journal-title":"Neuro Oncol."},{"issue":"1","key":"2026051303211725300_CIT0153","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ccell.2019.06.002","article-title":"A C19MC-LIN28A-MYCN oncogenic circuit driven by hijacked super-enhancers is a distinct therapeutic vulnerability in ETMRs: a lethal brain tumor","volume":"36","author":"Sin-Chan","year":"2019","journal-title":"Cancer Cell."},{"issue":"10","key":"2026051303211725300_CIT0154","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/nm.4402","article-title":"A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors","volume":"23","author":"Neumann","year":"2017","journal-title":"Nat Med."},{"issue":"5","key":"2026051303211725300_CIT0155","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/neuonc\/noad265","article-title":"Integrated proteomics spotlight the proteasome as a therapeutic vulnerability in embryonal tumors with multilayered rosettes","volume":"26","author":"Dottermusch","year":"2024","journal-title":"Neuro Oncol."},{"issue":"6","key":"2026051303211725300_CIT0156","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s43018-025-00964-9","article-title":"Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor\u2013ligand interactions","volume":"6","author":"Beck","year":"2025","journal-title":"Nat Cancer."},{"issue":"8","key":"2026051303211725300_CIT0157","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"issue":"5","key":"2026051303211725300_CIT0158","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2016.01.015","article-title":"New brain tumor entities emerge from molecular classification of CNS-PNETs","volume":"164","author":"Sturm","year":"2016","journal-title":"Cell."},{"issue":"1","key":"2026051303211725300_CIT0159","first-page":"vdae144","article-title":"A human embryonic stem cell\u2013based model reveals the cell of origin of FOXR2-activated CNS neuroblastoma","volume":"6","author":"Royston","year":"2024","journal-title":"Neurooncol. Adv.."},{"issue":"8","key":"2026051303211725300_CIT0160","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.3390\/ijms22083913","article-title":"BCOR internal tandem duplication expression in neural stem cells promotes growth, invasion, and expression of PRC2 targets","volume":"22","author":"Nakata","year":"2021","journal-title":"Int J Mol Sci ."},{"issue":"50","key":"2026051303211725300_CIT0161","doi-asserted-by":"crossref","first-page":"83378","DOI":"10.18632\/oncotarget.13092","article-title":"Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy","volume":"7","author":"Paret","year":"2016","journal-title":"Oncotarget."},{"issue":"69","key":"2026051303211725300_CIT0162","doi-asserted-by":"crossref","first-page":"114210","DOI":"10.18632\/oncotarget.23174","article-title":"Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy","volume":"8","author":"Paret","year":"2017","journal-title":"Oncotarget."},{"issue":"2","key":"2026051303211725300_CIT0163","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-019-02111-y","article-title":"Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium Registry study","volume":"139","author":"Li","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2026051303211725300_CIT0164","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00401-019-02101-0","article-title":"Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations","volume":"139","author":"Pfaff","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"12","key":"2026051303211725300_CIT0165","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/neuonc\/noae128","article-title":"SNO-EANO-EURACAN consensus on management of pineal parenchymal tumors","volume":"26","author":"Liu","year":"2024","journal-title":"Neuro Oncol."},{"issue":"5","key":"2026051303211725300_CIT0166","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00401-021-02284-5","article-title":"Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study","volume":"141","author":"Liu","year":"2021","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2026051303211725300_CIT0167","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41467-020-15585-2","article-title":"Modeling germline mutations in pineoblastoma uncovers lysosome disruption-based therapy","volume":"11","author":"Chung","year":"2020","journal-title":"Nat Commun."},{"issue":"1","key":"2026051303211725300_CIT0168","first-page":"vdac056","article-title":"Pediatric pineoblastoma: a pooled outcome study of North American and Australian therapeutic data","volume":"4","author":"Hansford","year":"2022","journal-title":"Neurooncol Adv."},{"issue":"7508","key":"2026051303211725300_CIT0169","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nature13296","article-title":"Novel somatic and germline mutations in intracranial germ cell tumours","volume":"511","author":"Wang","year":"2014","journal-title":"Nature."},{"issue":"34","key":"2026051303211725300_CIT0170","doi-asserted-by":"crossref","first-page":"55026","DOI":"10.18632\/oncotarget.10392","article-title":"CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras\/Raf\/Erk- and Akt-pathways","volume":"7","author":"Schulte","year":"2016","journal-title":"Oncotarget."},{"issue":"7","key":"2026051303211725300_CIT0171","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3390\/jpm11070661","article-title":"Molecular pathology and targeted therapies for personalized management of central nervous system germinoma","volume":"11","author":"Ilcus","year":"2021","journal-title":"J Pers Med."},{"issue":"6","key":"2026051303211725300_CIT0172","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00401-014-1247-5","article-title":"Mutually exclusive mutations of KIT and RAS are associated with KIT mRNA expression and chromosomal instability in primary intracranial pure germinomas","volume":"127","author":"Fukushima","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"6","key":"2026051303211725300_CIT0173","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00401-016-1557-x","article-title":"Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy","volume":"131","author":"Ichimura","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"9","key":"2026051303211725300_CIT0174","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1002\/pbc.24567","article-title":"Feasibility of dasatinib in children and adolescents with new or recurrent central nervous system germinoma","volume":"60","author":"Osorio","year":"2013","journal-title":"Pediatr Blood Cancer."},{"issue":"12","key":"2026051303211725300_CIT0175","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/neuonc\/noz139","article-title":"Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT Consortium","volume":"21","author":"Takami","year":"2019","journal-title":"Neuro Oncol."},{"issue":"3","key":"2026051303211725300_CIT0176","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/biomedicines6030086","article-title":"Emerging medical treatments for meningioma in the molecular era","volume":"6","author":"Nigim","year":"2018","journal-title":"Biomedicines."},{"issue":"21","key":"2026051303211725300_CIT0177","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2217\/fon-2018-0006","article-title":"An overview of meningiomas","volume":"14","author":"Buerki","year":"2018","journal-title":"Future Oncol."},{"issue":"11","key":"2026051303211725300_CIT0178","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol."},{"issue":"5","key":"2026051303211725300_CIT0179","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.neurol.2023.03.006","article-title":"Innovative treatments for meningiomas","volume":"179","author":"Graillon","year":"2023","journal-title":"Rev Neurol (Paris)."},{"issue":"6123","key":"2026051303211725300_CIT0180","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science."},{"issue":"1","key":"2026051303211725300_CIT0181","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41525-017-0014-7","article-title":"Genomic landscape of high-grade meningiomas","volume":"2","author":"Bi","year":"2017","journal-title":"NPJ Genom Med."},{"issue":"suppl 1","key":"2026051303211725300_CIT0182","doi-asserted-by":"crossref","first-page":"i18","DOI":"10.1093\/neuonc\/noy136","article-title":"Advances in multidisciplinary therapy for meningiomas","volume":"21","author":"Brastianos","year":"2019","journal-title":"Neuro Oncol."},{"issue":"2","key":"2026051303211725300_CIT0183","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2017.168","article-title":"Advances in meningioma genetics: novel therapeutic opportunities","volume":"14","author":"Preusser","year":"2018","journal-title":"Nat Rev Neurol."},{"issue":"1","key":"2026051303211725300_CIT0184","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00401-019-02095-9","article-title":"YAP1-fusions in pediatric NF2-wildtype meningioma","volume":"139","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"suppl 1","key":"2026051303211725300_CIT0185","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/neuonc\/noy178","article-title":"Molecular and translational advances in meningiomas","volume":"21","author":"Suppiah","year":"2019","journal-title":"Neuro Oncol."},{"issue":"6","key":"2026051303211725300_CIT0186","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/CCO.0000000000000687","article-title":"Molecular alterations in meningioma: prognostic and therapeutic perspectives","volume":"32","author":"Birzu","year":"2020","journal-title":"Curr Opin Oncol."},{"issue":"6","key":"2026051303211725300_CIT0187","doi-asserted-by":"crossref","first-page":"75","DOI":"10.21037\/cco-20-168","article-title":"A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base","volume":"9","author":"Martinez","year":"2020","journal-title":"Chin Clin Oncol."},{"issue":"6","key":"2026051303211725300_CIT0188","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1215\/15228517-2009-010","article-title":"Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)","volume":"11","author":"Wen","year":"2009","journal-title":"Neuro Oncol."},{"issue":"15","key":"2026051303211725300_CIT0189","doi-asserted-by":"crossref","first-page":"16041","DOI":"10.1002\/cam4.6254","article-title":"The role of radiation therapy and systemic treatments in meningioma: the present and the future","volume":"12","author":"Caccese","year":"2023","journal-title":"Cancer Med."},{"issue":"11","key":"2026051303211725300_CIT0190","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/14737175.2023.2254498","article-title":"Advances in the systemic therapy for recurrent meningiomas and the challenges ahead","volume":"23","author":"Li","year":"2023","journal-title":"Expert Rev Neurother."},{"issue":"2","key":"2026051303211725300_CIT0191","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","article-title":"A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma","volume":"129","author":"Shih","year":"2016","journal-title":"J Neurooncol."},{"issue":"2","key":"2026051303211725300_CIT0192","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-011-0687-1","article-title":"Phase II study of Gleevec\u00ae plus hydroxyurea (HU) in adults with progressive or recurrent meningioma","volume":"106","author":"Reardon","year":"2012","journal-title":"J Neurooncol."},{"issue":"1","key":"2026051303211725300_CIT0193","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol."},{"issue":"24","key":"2026051303211725300_CIT0194","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa2400985","article-title":"Brigatinib in NF2-related schwannomatosis with progressive tumors","volume":"390","author":"Plotkin","year":"2024","journal-title":"N Engl J Med."},{"issue":"3","key":"2026051303211725300_CIT0195","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.21.02371","article-title":"Alliance A071401: Phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations","volume":"41","author":"Brastianos","year":"2023","journal-title":"J Clin Oncol."},{"issue":"suppl 8","key":"2026051303211725300_CIT0196","doi-asserted-by":"crossref","first-page":"CT006","DOI":"10.1158\/1538-7445.AM2023-CT006","article-title":"Abstract CT006: first-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)\/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations","volume":"83","author":"Yap","year":"2023","journal-title":"Cancer Res."},{"issue":"3","key":"2026051303211725300_CIT0197","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11102-022-01212-4","article-title":"Targeted therapies in the medical management of craniopharyngioma","volume":"25","author":"Iglesias","year":"2022","journal-title":"Pituitary."},{"issue":"5","key":"2026051303211725300_CIT0198","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","article-title":"Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target","volume":"135","author":"Apps","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2026051303211725300_CIT0199","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1210\/endrev\/bnac035","article-title":"Contemporary biological insights and clinical management of craniopharyngioma","volume":"44","author":"Apps","year":"2023","journal-title":"Endocr Rev."},{"issue":"6","key":"2026051303211725300_CIT0200","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.3171\/2016.8.FOCUS16307","article-title":"Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice","volume":"41","author":"Apps","year":"2016","journal-title":"Neurosurg Focus."},{"issue":"1","key":"2026051303211725300_CIT0201","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s40478-024-01838-4","article-title":"Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression","volume":"12","author":"Apps","year":"2024","journal-title":"Acta Neuropathol Commun."},{"issue":"3","key":"2026051303211725300_CIT0202","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/ERC-18-0538","article-title":"SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma","volume":"26","author":"Carreno","year":"2019","journal-title":"Endocr Relat Cancer."},{"issue":"9","key":"2026051303211725300_CIT0203","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jnen\/nlx061","article-title":"Molecular analyses reveal inflammatory mediators in the solid component and cyst fluid of human adamantinomatous craniopharyngioma","volume":"76","author":"Donson","year":"2017","journal-title":"J Neuropathol Exp Neurol."},{"issue":"12","key":"2026051303211725300_CIT0204","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.2009.26.8169","article-title":"TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors","volume":"28","author":"Tabori","year":"2010","journal-title":"J Clin Oncol."},{"issue":"7","key":"2026051303211725300_CIT0205","doi-asserted-by":"crossref","first-page":"e27031","DOI":"10.1002\/pbc.27031","article-title":"Pediatric choroid plexus carcinoma: biologically and clinically in need of new perspectives","volume":"65","author":"Zaky","year":"2018","journal-title":"Pediatr Blood Cancer."},{"issue":"1","key":"2026051303211725300_CIT0206","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/1078-0432.CCR-14-1324","article-title":"Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups","volume":"21","author":"Merino","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2026051303211725300_CIT0207","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2353\/ajpath.2009.081022","article-title":"Platelet-derived growth factor receptor expression and activation in choroid plexus tumors","volume":"175","author":"Koos","year":"2009","journal-title":"Am J Pathol."},{"issue":"3","key":"2026051303211725300_CIT0208","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/modpathol.3800989","article-title":"Platelet-derived growth factor receptor expression and amplification in choroid plexus carcinomas","volume":"21","author":"Nupponen","year":"2008","journal-title":"Mod Pathol."},{"issue":"6","key":"2026051303211725300_CIT0209","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/neuonc\/noac274","article-title":"Molecular heterogeneity of pediatric choroid plexus carcinomas determines the distinctions in clinical course and prognosis","volume":"25","author":"Zaytseva","year":"2023","journal-title":"Neuro Oncol."},{"key":"2026051303211725300_CIT0210","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jconrel.2023.04.016","article-title":"Preclinical validation of a novel therapeutic strategy for choroid plexus carcinoma","volume":"357","author":"Martin","year":"2023","journal-title":"J Control Release."},{"issue":"1","key":"2026051303211725300_CIT0211","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11060-023-04484-3","article-title":"Multi-omics analyses of choroid plexus carcinoma cell lines reveal potential targetable pathways and alterations","volume":"166","author":"Hesham","year":"2024","journal-title":"J Neurooncol."},{"issue":"4","key":"2026051303211725300_CIT0212","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ncb3327","article-title":"Sonic Hedgehog promotes proliferation of Notch-dependent monociliated choroid plexus tumour cells","volume":"18","author":"Li","year":"2016","journal-title":"Nat Cell Biol."},{"issue":"1","key":"2026051303211725300_CIT0213","first-page":"vdae109","article-title":"Marrow-ablative consolidation chemotherapy and molecular targeted therapy delivered in a risk-adapted manner for newly diagnosed children with choroid plexus carcinoma: a work in progress","volume":"6","author":"Yankelevich","year":"2024","journal-title":"Neurooncol Adv."},{"issue":"1","key":"2026051303211725300_CIT0214","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s40478-024-01886-w","article-title":"High detection rate of circulating-tumor DNA from cerebrospinal fluid of children with central nervous system germ cell tumors","volume":"12","author":"Nakano","year":"2024","journal-title":"Acta Neuropathol Commun."},{"issue":"1","key":"2026051303211725300_CIT0215","doi-asserted-by":"crossref","first-page":"14326","DOI":"10.1038\/s41598-020-71161-0","article-title":"Cerebrospinal fluid ctDNA and metabolites are informative biomarkers for the evaluation of CNS germ cell tumors","volume":"10","author":"Takayasu","year":"2020","journal-title":"Sci Rep."},{"issue":"11","key":"2026051303211725300_CIT0216","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.ccell.2021.09.012","article-title":"Serial assessment of measurable residual disease in medulloblastoma liquid biopsies","volume":"39","author":"Liu","year":"2021","journal-title":"Cancer Cell."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf188\/67301700\/vdaf188.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/Supplement_2\/ii78\/67301700\/vdaf188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/Supplement_2\/ii78\/67301700\/vdaf188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:21:51Z","timestamp":1778656911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/8\/Supplement_2\/ii78\/8514394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":216,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf188","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,12,2]]}}}